Prognostic Factors Affecting Outcome after Allogeneic
Transplantation for Hematological Malignancies from Unrelated
Donors: Results from a Randomized Trial

J 2012

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial

FINKE, Juergen; Claudia SCHMOOR; Wolfgang A. BETHGE; Hellmut D. OTTINGER; Matthias STELLJES et al.

Základní údaje

Originální název

Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial

Autoři

Vydání

Biology of Blood and Marrow Transplantation, New York, USA, ELSEVIER SCIENCE, 2012, 1083-8791

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.940

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00063576

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.bbmt.2012.06.001

UT WoS

000310493700013

Klíčová slova anglicky

Allogeneic hematopoietic stem-cell transplantation; Graft-versus-host-disease prophylaxis; HLA-matching

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 2. 2013 11:45, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRBI, HLA-DQBI allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age >= 40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD.

Přiložené soubory

Image.pdf

Požádat o autorskou verzi souboru

Citovat

FINKE, Juergen; Claudia SCHMOOR; Wolfgang A. BETHGE; Hellmut D. OTTINGER; Matthias STELLJES; Axel R. ZANDER; Liisa VOLIN; Dominik A. HEIM; Rainer SCHWERDTFEGER; Karin KOLBE; Jiří MAYER; Johan A. MAERTENS; Werner LINKESCH; Ernst HOLLER; Vladimír KOZA; Martin BORNHAEUSER; Hermann EINSELE; Hartmut BERTZ; Olga GRISHINA a Gerard SOCIE. Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. Biology of Blood and Marrow Transplantation. New York, USA: ELSEVIER SCIENCE, 2012, roč. 18, č. 11, s. 1716-1726. ISSN 1083-8791. Dostupné z: https://doi.org/10.1016/j.bbmt.2012.06.001.

@article{1085718,
   author = {Finke, Juergen and Schmoor, Claudia and Bethge, Wolfgang A. and Ottinger, Hellmut D. and Stelljes, Matthias and Zander, Axel R. and Volin, Liisa and Heim, Dominik A. and Schwerdtfeger, Rainer and Kolbe, Karin and Mayer, Jiří and Maertens, Johan A. and Linkesch, Werner and Holler, Ernst and Koza, Vladimír and Bornhaeuser, Martin and Einsele, Hermann and Bertz, Hartmut and Grishina, Olga and Socie, Gerard},
   article_location = {New York, USA},
   article_number = {11},
   doi = {https://doi.org/10.1016/j.bbmt.2012.06.001},
   keywords = {Allogeneic hematopoietic stem-cell transplantation; Graft-versus-host-disease prophylaxis; HLA-matching},
   language = {eng},
   issn = {1083-8791},
   journal = {Biology of Blood and Marrow Transplantation},
   title = {Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial},
   volume = {18},
   year = {2012}
}

TY  - JOUR
ID  - 1085718
AU  - Finke, Juergen - Schmoor, Claudia - Bethge, Wolfgang A. - Ottinger, Hellmut D. - Stelljes, Matthias - Zander, Axel R. - Volin, Liisa - Heim, Dominik A. - Schwerdtfeger, Rainer - Kolbe, Karin - Mayer, Jiří - Maertens, Johan A. - Linkesch, Werner - Holler, Ernst - Koza, Vladimír - Bornhaeuser, Martin - Einsele, Hermann - Bertz, Hartmut - Grishina, Olga - Socie, Gerard
PY  - 2012
TI  - Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial
JF  - Biology of Blood and Marrow Transplantation
VL  - 18
IS  - 11
SP  - 1716-1726
EP  - 1716-1726
PB  - ELSEVIER SCIENCE
SN  - 10838791
KW  - Allogeneic hematopoietic stem-cell transplantation
KW  - Graft-versus-host-disease prophylaxis
KW  - HLA-matching
N2  - Several prognostic factors for the outcome after allogeneic hematopoietic stem-cell transplant (HSCT) from matched unrelated donors have been postulated from registry data; however, data from randomized trials are lacking. We present analyses on the effects of patient-related, donor-related, and treatment-related prognostic factors on acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) in a randomized, multicenter, open-label, phase III trial comparing standard graft-versus-host-disease (GVHD) prophylaxis with and without pretransplantation ATG-Fresenius (ATG-F) in 201 adult patients receiving myeloablative conditioning before HSCT from HLA-A, HLA-B antigen, HLA-DRBI, HLA-DQBI allele matched unrelated donors. High-resolution testing (allele) of HLA-A, HLA-B, and HLA-C were obtained after study closure, and the impact of an HLA 10/10 4-digit mismatch on outcome and on the treatment effect of ATG-F versus control investigated. Advanced disease was a negative factor for relapse, DFS, and OS. Donor age >= 40 adversely affected the risk of aGVHD III-IV, extensive cGVHD, and OS. Younger donors are to be preferred in unrelated donor transplantation. Advanced disease patients need special precautions to improve outcome. The degree of mismatch had no major influence on the positive effect of ATG-F on the reduction of aGVHD and cGVHD.
ER  -

FINKE, Juergen; Claudia SCHMOOR; Wolfgang A. BETHGE; Hellmut D. OTTINGER; Matthias STELLJES; Axel R. ZANDER; Liisa VOLIN; Dominik A. HEIM; Rainer SCHWERDTFEGER; Karin KOLBE; Jiří MAYER; Johan A. MAERTENS; Werner LINKESCH; Ernst HOLLER; Vladimír KOZA; Martin BORNHAEUSER; Hermann EINSELE; Hartmut BERTZ; Olga GRISHINA a Gerard SOCIE. Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. \textit{Biology of Blood and Marrow Transplantation}. New York, USA: ELSEVIER SCIENCE, 2012, roč.~18, č.~11, s.~1716-1726. ISSN~1083-8791. Dostupné z: https://doi.org/10.1016/j.bbmt.2012.06.001.

Přehled o publikaci